REMARKS

Applicant made an inadvertent error in SEQ ID NO: 1 in the specification (see page 40 of the pending U.S. Provisional Patent Application No. 60/458,946 to which this application claims priority). SEQ ID NO:1 is a full-length amino acid sequence of a wild-type human PDE1B. This sequence was published prior to the filing date of the pending provisional referred to above, e.g., see Cell. Signal. 9:519-526, specifically, page 522 (1997) (attached for the Examiner's convenience). This paper is described in the specification of the pending provisional noted above, together with the specification of the application being filed concurrent herewith, e.g., see page 3, line 13 (pending provisional) and page 3, line 17 (application being filed concurrent herewith). Applicant inadvertently listed the first 60 amino acids at the end of the sequence versus in their rightful place at the beginning, as amino acids 1-60. Applicant is filing this preliminary amendment to merely correct the positioning of the first 60 amino acids. As the Examiner will fully appreciate, no new matter is being added by this amendment, given that Applicant had described the above article in the specification of the pending provisional to which the application being filed concurrent herewith claims priority. Pending entry of the amendment, SEQ ID NO:1, once again, a sequence in the public domain prior to the filing date of the pending provisional to which the application being filed concurrent herewith claims priority will now correctly reflect the sequence published in the above noted article.

Applicant regrets any inconvenience to the Examiner due to Applicant's inadvertent error, and respectfully requests entry of the amendment hereinabove, and an early examination and allowance of the claims.

Date: 3/31/04

Respectfully submitted,

Irene M. Reininger O Attorney for Applicant Reg. No. 48,439

Pfizer Inc Eastern Point Road MS 8260-1611 Groton, CT 06340 (860) 715-5756

GCA GCG GGA GAG GAG GAG CCG CAG GAG CTG CAG CTC TGC CAG CTT GGG CCG AGC CTA GAG ACA CCG GCC TGG CTG 75 GTC CAC GCC AGC CGC AGA CCG TGG CTG AGC ATG GAG CTG TCA CCC CGC AGT CCT CCG GAG ATG CTG GAG GAG TCG 150 8 GAT TGC CCG TCA CCC CTG GAG CTG AAG TCA GCC CCC AGC AAG AAG ATG TGG ATT AAG CTT CGG TCT CTG CTG CGC 225 8 K K TAC ATG GTG AAG CAG TTG GAG AAT GGG GAG ATA AAC ATT GAG GAG CTG AAG AAA AAT CTG GAG TAC ACA GCT TCT 300 41 CTG GAA GCC GTC TAC ATA GAT GAG ACA CGG CAA ATC TTG GAC ACG GAG GAC GAG CTG CAG GAG CTG CGG TCA 375 450 GCA GAG GAG AAG CCC AAG TTC CGA AGC ATT GTG CAC GCT GTG CAG GCT GGG ATC TTC GTG GAA CGG ATG TTC CGG 116 AGA ACA TAC ACC TCT GTG GGC CCC ACT TAC TCT ACT GCG GTT CTC AAC TGT CTC AAG AAC CTG GAT CTC TGG TGC TTT GAT GTC TTT TCC TTG AAC CAG GCA GCA GAT GAC CAT GCC CTG AGG ACC ATT GTT TTT GAG TTG CTG ACT CGG
F D V F S L N Q A A D D H A L R T I V F E L L T R 675 166 750 GGG AAG TAC AAG AAT CCT TAC CAC AAC CAG ATC CAC GCA GCC GAT GTT ACC CAG ACA GTC CAT TGC TTC TTG CTC 825 CGC ACA GGG ATG GTG CAC TGC CTG TCG GAG ATT GAG CTC CTG GCC ATC ATC TTT GCT GCA GCT ATC CAT GAT TAT 900 241 GAG CAC ACG GGC ACT ACC AAC AGC TTC CAC ATC CAG ACC AAG TCA GAA TGT GCC ATC GTG TAC AAT GAT CGT TCA 975 Ħ I Q GTG CTG GAG AAT CAC CAC ATC AGC TCT GTT TTC CGA TTG ATG CAG GAT GAT GAG ATG AAC ATT TTC ATC AAC CTC 1050 ACC AAG GAT GAG TTT GTA GAA CTC CGA GCC CTG GTC ATT GAG ATG GTG TTG GCC ACA GAC ATG TCC TGC CAT TTC 1125 CAG CAA GTG AAG ACC ATG AAG ACA GCC TTG CAA CAG CTG GAG AGG ATT GAC AAG CCC AAG GCC CTG TCT CTA CTG Q Q V K T M K T A L Q Q L E R I D K P K A L S L L 1200 341 CTC CAT GCT GCT GAC ATC AGC CAC CCA ACC AAG CAG TGG TTG GTC CAC AGC CGT TGG ACC AAG GCC CTC ATG GAG 366 Q H GAA TTC TTC CGT CAG GGT GAC AAG GAG GCA GAG TTG GGC CTG CCC TTT TCT CCA CTC TGT GAC CGC ACT TCC ACT 1350 CTA GTG GCA CAG TCT CAG ATA GGG TTC ATC GAC TTC ATT GTG GAG CCC ACA TTC TCT GTG CTG ACT GAC GTG GCA 1425 416 , D GAG AAG AGT GTT CAG CCC CTG GCG GAT GAG GAC TCC AAG TCT AAA AAC CAG CCC AGC TTT CAG TGG CGC CAG CCC 1500 441 P D D 8 8 TCT CTG GAT GTG GAA GTG GGA GAC CCC AAC CCT GAT GTG GTC AGC TTT CGT TCC ACC TGG GTC AAG CGC ATT CAG 1575 gag aac aag cag aaa teg aag gaa ceg gca gca agt ggc atc acc aac cag atg tec att gac gag etg tec ecc 1650 I 8 I D Q TGT GAA GAA GAG GCC CCC CCA TCC CCT GCC GAA GAT GAA CAC AAC CAG AAT GGG AAT CTG GAT TAG CCC TGG GGC 1725 516 TGG CCC AGG TCT TCA TTG AGT CCA AAG TGT TTG ATG TCA TCA GCA CCA TCC ATC AGG ACT GGC TCC CCC ATC TGC 1800 TCC AAG GGA GCG TGG TCG TGG AAA CAA CCC ACC TGA AGG CCA AAT GCC AGA GAT TTG GGG TTG GGG AAA GGG 1875 CCC CTC CCC ACC TGA CAC CCA CTG GGG TGC ACT TTA ATG TTC CGG CAG CAA GAC TGG GGA ACT TCA GGC TCC CAG 1950 TGG TCA CTG TGC CCA TCC CTC AGC CTC TGG ATT CTC TTC ATG GCC AGG TGG CTG CCA GGG AGC GGG GAG CTT CCT 2025 GGA GGC TTC CCA GGG CCT TGG GGA AGG GTC AGA GAT GCC AGC CCC CTG GGA CCT CCC CCA TCC TTT TTG CCT CCA 2100 AGT TTC TAA GCA ATA CAT TTT GGG GGT TCC CTC AGC CCC CCA CCC CAG ATC TTA GCT GGC AGG TCT GGG TGC CCC 2175 TTT TCC TCC CCT GGG AAG GGC TGG AAT AGG ATA GAA AGC TGG GGG TTT TCA GAG CCC TAT GTG TGG GGA GGG GAG 2250 TGG ATT CCT TCA GGG CAT GGT ACC TTT CTA GGA CCT GGG AAT GGG GTG GAG AGG ACG TCC TCT TCA CCC CAG AAT 2325 TGC GCT GCT TCA GCC CCA TCT CCA GCC TGA TCC TCT GAA TCT TCC TTC CCT CCC TTT CTG ATA TAG TGA CTG GGG 2400 CAA AAG GAG CCA TTG TGA CCA GGG GCT GCG GGA GGC CTT TCC TGG GAC CTT CCT TGG GAC TGG TCT GGG CCC TGG 2475 GGT TTG TCG CCT GCC CTG AGT CCG GAG CCC TTT GCC TCC TTC CTC TCC CCT GGG GCT GGG AGG CTC CAT CCG ACC 2550 AAT GTC TGT AAA GTG CTT TGA GGA TCT CCC CAG CAA AGC ACC TTC AGA ATG TAT CGA CAC CAG CTG GGT TAG GGT 2625 CAA GGG TGC CTG GGG AGG G 2644

FIGURE 1. Nucleotide and predicted protein sequence of HSPDE1B1 cDNA. The cDNA sequence shown was constructed from overlapping sequences of clones FB56a (nucleotides 1–698) and FB29a (nucleotides 285–2644) isolated from a human foetal brain cDNA library. Nucleotide residues are numbered on the right. The predicted amino acid sequence is represented by single letter amino acid code beneath the nucleotide sequence and is numbered on the left.

of approximately 750 bp is obtained due to the presence of intronic sequences between the primers. No product of the expected size is obtained when either mouse or hamster genomic DNA is used as template.

PCR (12.5 µl) was carried out with 0.1 U Taq Polymerase, 0.2 mM dNTPs, and 10 µg/ml of each primer in standard reaction buffer (Boehringer Mannheim). Somatic cell hybrid DNA (0.25 µl, representing 61–93 ng) was added as